Remus Pharmaceuticals Q4 FY26 Results: PAT Rs 25 Cr

Remus Pharmaceuticals Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 25 crore for the quarter ended March 31, 2026, up 19.0% YoY compared to Rs 21 crore in Q4 FY25. Revenue from operations stood at Rs 453 crore. Results are on a Consolidated basis. Remus Pharmaceuticals is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Remus Pharmaceuticals Q4 FY26 Financial Highlights

Note: Remus Pharmaceuticals Q4 FY26 results declared May 20, 2026. Data sourced from Screener.in BSE filings. Verify from BSE/NSE audited financials before investment decisions.

Remus Pharmaceuticals Q4 FY26 Performance Analysis

The Remus Pharmaceuticals Q4 FY26 results reflect the company’s financial performance for the January to March 2026 quarter. The quarter demonstrates meaningful profitability with PAT of Rs 25 crore, reflecting strong operational execution. Remus Pharmaceuticals operates in the Pharmaceuticals sector, a segment that benefits from India’s GDP growth above 6.5% and sustained domestic demand in FY26.

The 19.0% YoY PAT growth in Remus Pharmaceuticals Q4 FY26 reflects the company’s improving operational efficiency and demand conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Remus Pharmaceuticals Q4 FY26 Results

Revenue and Operational Performance

Remus Pharmaceuticals Q4 FY26 revenue of Rs 453 crore reflects the seasonal and demand dynamics of the Pharmaceuticals sector during the January to March 2026 quarter. India’s robust macroeconomic backdrop with GDP above 6.5%, government capital expenditure continuity, and resilient domestic consumption supported demand across sectors.

Profitability Trends

The Remus Pharmaceuticals Q4 FY26 PAT of Rs 25 crore up 19.0% YoY. Margin improvement and operating leverage will be the primary levers for sustaining profitability in FY27.

India Macro Context

The January to March 2026 quarter was the fiscal year-end quarter for Indian companies. India’s Union Budget FY27 allocated Rs 11.21 lakh crore in capital expenditure, and the RBI maintained accommodative liquidity conditions. These macro factors supported demand conditions across manufacturing, services, and consumer sectors during the quarter, benefiting companies operating in the Pharmaceuticals space like Remus Pharmaceuticals.

FY27 Outlook

Following Remus Pharmaceuticals Q4 FY26 results, investors will monitor management guidance on FY27 revenue trajectory, margin improvement roadmap, and capital allocation priorities. The Pharmaceuticals sector outlook for FY27 is supported by India’s structural growth drivers including urbanisation, infrastructure investment, and rising consumption.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Remus Pharmaceuticals Q4 FY26

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.